News & Videos - FLYING BRANDS LD ORD GBP0.01

MILWAUKEE, WI / ACCESSWIRE / July 13, 2023 / Imaging Biometrics, LLC (IB) , a wholly-owned subsidiary of IQ-AI Ltd (LSE:IQAI)(OTCQB:IQAIF) , today announced the U.S. Food and Drug Administration (US FDA) has granted Orphan Drug Designation (ODD) for gallium maltolate (GaM) for the treatment of pediatric glioblastoma multiforme (GBM). In February, IB was granted Orphan Drug Designation for adult GBM. The US FDA has since confirmed that the designation granted in February applies to both adult and...

MILWAUKEE, WI / ACCESSWIRE / February 28, 2023 / IQ-AI Limited, (OTCQB:IQAIF)(LSE:IQAI) , and its US-based subsidiary, Imaging Biometrics, LLC (Milwaukee, WI) is pleased to announce that the United States Food and Drug Administration (FDA) has granted orphan drug designation (ODD) status for gallium maltolate (GaM) for the treatment of glioblastoma multiforme (GBM) brain cancer. GaM is the oral agent under study in IQAI's sponsored Phase I clinical trial being conducted at the Medical College of...

Patented Artificial Intelligence Technology Eliminates the Need for Gadolinium-Based Contrast Agents in MRI Exams MILWAUKEE, WI / ACCESSWIRE / May 31, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF) (LSE:IQAI) , today announced it has submitted an FDA 510(k) application for IB Zero G™; the patented artificial intelligence (AI) software that eliminates the need for gadolinium-based contrast agents ("GBCAs") in routine magnetic resonance imaging ("MRI") exams....

Study Shows DSC MRI Perfusion Distinguishes Tumor from Non-Tumor Tissue MILWAUKEE, WI / ACCESSWIRE / May 3, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF)(LSE:IQAI) , notes a recent study published in the American Journal of Neuroradiology entitled: DSC Perfusion-Derived Fractional Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery . The retrospective study, led by Dr....

MILWAUKEE, WI / ACCESSWIRE / March 10, 2022 / IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI) is pleased to announce that the sponsored Phase I clinical trial for oral gallium maltolate (GaM) is open for enrollment. The trial is being led by Dr. Jennifer Connelly, MD, Associate Professor of Neurology, and Dr. Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology, both at the Medical College of Wisconsin (MCW). Patient recruitment in the trial is...

Panel of International Experts Deem MR DSC Perfusion as Most Clinically Validated MILWAUKEE, WI / ACCESSWIRE / March 7, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF) (LSE:IQAI), is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe. The paper, published in Frontiers in Oncology , was written by a team of clinicians, engineers, and physicists working on behalf of the European...

Imaging Biometrics, a subsidiary of IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI), discusses its most successful year on record. Increases technology platform and expects record revenues Rolls out Phase I clinical trial and prepares to file 510(K) with the FDA MILWAUKEE, WI / ACCESSWIRE / January 27, 2022 / Imaging Biometrics, a subsidiary of London-based IQ-AI Limited, develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat disease, today...

IB Zero G™ Technology May Benefit Imaging in Pediatric Patients MILWAUKEE, WI / ACCESSWIRE / November 11, 2021 / IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI) , a developer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, and St. Jude Children's Hospital (Memphis, TN), have entered into a Data Use Agreement. The Agreement is a specific type of agreement required under the Health Insurance Portability and Accountability Act...

Installation Includes IB Neuro™ and IB DCE™ Software Purchase also Includes IB Clinic - Mac Edition MILWAUKEE, WI / ACCESSWIRE / November 2, 2021 / IQ-AI Limited (LSE:IQAI)(OTCQB:IQAIF) , a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, today announced the University of Texas MD Anderson Cancer Center (Houston, TX) is the latest brain cancer center to purchase an annual subscription of IB...

Company Enjoys Most Successful Year on Record Marked Increase in Revenue and Growing Technology Portfolio Sponsorship of a Phase I Clinical Trial MILWAUKEE, WI / ACCESSWIRE / October 28, 2021 / IQ-AI Limited (OTCQB:IQAIF) (LSE:IQAI) , a developer and manufacturer of medical image processing platforms, released a letter to shareholders from Director Michael Schmainda. The entire letter follows: Dear Shareholders: The intent of this inaugural quarterly letter is to share our optimism with our...

Affiliated Hospital Purchases IB Clinic for Automated Analysis MILWAUKEE, WI / ACCESSWIRE / October 1, 2021 / IQ-AI Limited (LSE:IQAI) (OTCQB:IQAIF) , a developer and manufacturer of medical image processing platforms announced a recent publication in Neurosurgery Open that illustrates the clinical impact of its neuro oncology software solutions for both neurosurgery and tissue diagnosis of high-grade brain tumors. The on-going challenge with the treatment of brain tumors is that new or...

MILWAUKEE, WI / ACCESSWIRE / September 22, 2021 / IQ-AI Limited (LSE:IQAI) (OTCQB:IQAIF) , a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies that prolong survival and improve the quality of life in brain tumor and other patients, today announced it has been awarded a European Patent for "Multiparameter Perfusion Imaging with Leakage Correction". Already patented in the USA, this technology, also referred to loosely as...

Sales of Renewal Licenses for Established Clients and a New Installation of IB Clinic at the Eastern Alabama Medical Center MILWAUKEE, WI / ACCESSWIRE / September 20, 2021 / Q-AI Limited (LSE:IQAI) (OTCQB:IQAIF) , a developer and manufacturer of medical image processing platforms that have led to effective therapeutic strategies that prolong survival and improve the quality of life in brain tumor and other patients, today announced the sale of multiple licenses of its Imaging Biometrics (IB)...